Christian Ramirez Amarilla talks about METTL3 atBITS2024

A new therapeutic has recently been FDA-approved, revumenib, for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients. GTC's Liquid Trace and Hematology Profile Plus can help identify patients who are candidates for this therapeutic. https://lnkd.in/gBmGD6u #KMT2A #Leukemia 

A new therapeutic has recently been FDA-approved, revumenib, for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients. GTC's Liquid Trace and Hematology Profile Plus can help identify patients who are candidates for this therapeutic. https://lnkd.in/gBmGD6u #KMT2A #Leukemia 

Next-generation sequencing for acute myeloid leukemia (AML) provides increased accuracy for clinically relevant genes. Learn more about our comprehensive 47-gene panel and our focused AML subpanels. https://bit.ly/4fKSIde

A new therapeutic has recently been FDA-approved, revumenib, for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients. GTC's Liquid Trace and Hematology Profile Plus can help identify patients who are candidates for this therapeutic. https://lnkd.in/gBmGD6u #KMT2A #Leukemia 

The OncoAlert 🚨Newsletter NOW OUT Covering July 26-Aug 1, 2024 REGISTER at www.Oncoalert360.com or https://lnkd.in/d7QR5f-6 Discussing ✅Shield Blood test FDA🇺🇸Approved for #ColorectalCancer Screening ✅INSIGHT Trial in #NSCLC 🫁 ✅ASCO🪴Guidelines on cannabis in Adults Cancer ✅Combining PSMA-PET☢️and PROMISE in #ProstateCancer ✅Review in RCC #KidneyCancer Bernadett Szabados Thomas Powles,MD Dr Francesca Jackson-Spence ✅Immune & Gene Expression🧬in ER Low & Neg #BreastCancer by Maria Vittoria Dieci ✅Top Advances of the year: #Immunotherapy 🧪& #EndometrialCancer Susana Banerjee ✅Health Outcomes of Older adults with #MultipleMyeloma 🧓 Supriya Maheshwari Grant Williams MD, MSPH, FASCO Smith Giri, MD MHS ✅Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome+ ALL

FDA has approved revumenib to treat relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation. Regulators were convinced by promising results in a sample of 104 pediatric and adult patients who received revumenib as part of a single-cohort, open-label study. Complete remission (CR) plus CR with partial hematologic recovery (CRh) was confirmed in 21.2% of trial participants, with the effect lasting for a median 6.4 months. Additionally, 12 of 83 patients who relied on red blood cell and/or platelet transfusions at baseline (14%) achieved independence from transfusions within 56 days of the baseline period. https://lnkd.in/gW7uZc4T

Gene&Cell Therapy >> Umoja’s $100M Series C will advance its bid for more convenient cell therapies: In the 10th megaround of 2025, Umoja Biopharma has banked $100 million in a Series C fundraise with an eye to advancing its pipeline of in vivo CAR-T cell therapies for cancer and autoimmune diseases ... #lucidquest #genetherapy #celltherapy

#HighlyCitedPapers   📝 Updates in KMT2A Gene Rearrangement in Pediatric Acute Lymphoblastic Leukemia — Górecki, et al.   The aim of this review is to summarize our knowledge and present current insight into the mechanisms of KMT2A-r ALL, portray their characteristics, discuss the clinical outcome along with risk stratification, and present novel therapeutic strategies.   Full text is available 👇 https://lnkd.in/dx3YHBUA   #medicine #health #research #science

Testing for BCR-ABL1 detects the Philadelphia chromosome and BCR-ABL1 fusion gene or it's transcripts, which are the RNA copies made by the cell from the abnormal stretches of DNA. The presence of the BCR-ABL1 abnormality confirms the clinical diagnosis of CML, a type of ALL, and rarely acute myeloid leukemia (AML). The picture below shows a derivative chromosome 22 resulting from a translocation between chromosomes 9 and 22 causing the BCR-ABL fusion.

💊🧬 Is JZP-458 the next-generation acute lymphoblastic leukemia drug?? 💊🧬 All the leukemias that occur in adults, acute lymphoblastic leukemia (ALL) is the second most prevalent type. Even though 80% of ALL cases are reported in younger age, it is a fatal disease when it affects adults. A bimodal distribution describes the incidence of ALL, with the first peak occurring in childhood and the second peak appearing at the age of 50 years. Chromosomal abnormalities and genetic changes affecting lymphoid precursor cell development and proliferation are the distinguishing features of ALL. 💡 Although EZP-458 is effective in ALL and LBL patients who were sensitive to asparaginase, it is associated with various adverse effects like recurrent infections, rise in blood glucose levels, increased neutrophil count, and bleeding. So further studies are required to improve its efficacy and reduce its side effects. 🩺 Read our blog @ https://lnkd.in/gmZYEMSv and explore the future of acute lymphoblastic leukemia treatment. #AcuteLymphoblasticLeukemia #ALL #JZP458 #CancerResearch #NextGenerationDrugs #Oncology #HealthcareInnovation #CancerTreatment #PersonalizedMedicine #LeukemiaCare #MedicalAdvancements #PharmaceuticalResearch #CancerAwareness #TargetedTherapy #HealthcareTechnology #CancerCare #ClinicalTrials #Biotechnology #PatientCare #FutureOfMedicine #Bhimar #Healthcare #LongevityAsia #OmicsFi #CellTalk